$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009563 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$205.0K	$164.8K	$989.0K
YoY Change	9.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$378.0K	$309.5K	$1.503M
YoY Change	-6.33%	-15.96%	2.66%
% of Gross Profit
Research & Development	$548.4K	$319.4K	$2.389M
YoY Change	-18.02%	-56.8%	-8.09%
% of Gross Profit
Depreciation & Amortization	$2.230K	$2.040K	$10.90K
YoY Change	-30.75%	-36.65%	-15.35%
% of Gross Profit
Operating Expenses	$987.2K	$630.9K	$4.417M
YoY Change	-8.23%	-43.2%	8.35%
Operating Profit	-$782.2K		-$3.428M
YoY Change	-21.78%		-26.63%
Interest Expense	-$45.24K	-$48.48K	-$163.3K
YoY Change	49.6%	199.63%	-83.11%
% of Operating Profit
Other Income/Expense, Net	-$45.24K	-$670.00	-$126.7K
YoY Change	46.58%	109.38%	-504.65%
Pretax Income	-$827.5K	-$732.7K	-$3.555M
YoY Change	-19.74%	-40.86%	-35.83%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$827.5K	-$732.7K	-$3.555M
YoY Change	-19.74%	-40.86%	-35.83%
Net Earnings / Revenue	-403.59%	-444.46%	-359.41%
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	419.5M shares	419.5M shares	419.5M shares
Diluted Shares Outstanding	419.5M shares		419.5M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.15K	$21.61K	$21.61K
YoY Change	-80.33%	-96.84%	-96.84%
Cash & Equivalents	$1.321M	$21.61K	$21.61K
Short-Term Investments
Other Short-Term Assets	$1.561M	$1.877M	$1.877M
YoY Change	-38.44%	-31.83%	-31.83%
Inventory
Prepaid Expenses		$467.1K
Receivables
Other Receivables
Total Short-Term Assets	$1.596M	$1.899M	$1.899M
YoY Change	-41.17%	-44.82%	-44.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.71K	$20.94K	$138.1K
YoY Change	-57.28%	-34.22%	93.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$124.8K	$138.1K	$138.1K
YoY Change	184.92%	93.37%	93.38%
TOTAL ASSETS
Total Short-Term Assets	$1.596M	$1.899M	$1.899M
Total Long-Term Assets	$124.8K	$138.1K	$138.1K
Total Assets	$1.720M	$2.037M	$2.037M
YoY Change	-37.57%	-42.01%	-42.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.908M	$2.094M	$2.094M
YoY Change	19.42%	62.67%	62.67%
Accrued Expenses	$2.914M	$2.520M	$2.520M
YoY Change	29.52%	22.06%	22.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due	$2.533M	$2.067M	$2.067M
YoY Change	72.88%	37.94%	37.94%
Total Short-Term Liabilities	$8.660M	$8.192M	$8.192M
YoY Change	10.68%	6.39%	6.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$61.75K	$73.38K	$73.38K
YoY Change
Total Long-Term Liabilities	$61.75K	$73.38K	$73.38K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.660M	$8.192M	$8.192M
Total Long-Term Liabilities	$61.75K	$73.38K	$73.38K
Total Liabilities	$8.722M	$8.266M	$8.266M
YoY Change	11.47%	7.34%	7.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$250.4M	-$249.6M
YoY Change		1.44%
Common Stock	$419.5K	$419.5K
YoY Change		0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.002M	-$6.229M	-$6.229M
YoY Change
Total Liabilities & Shareholders Equity	$1.720M	$2.037M	$2.037M
YoY Change	-37.57%	-42.01%	-42.01%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$827.5K	-$732.7K	-$3.555M
YoY Change	-19.74%	-40.86%	-35.83%
Depreciation, Depletion And Amortization	$2.230K	$2.040K	$10.90K
YoY Change	-30.75%	-36.65%	-15.35%
Cash From Operating Activities	-$624.1K	-$754.8K	-$3.041M
YoY Change	5.38%	-146.54%	200.16%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$515.7K	474.2K	$1.368M
YoY Change	-1638.03%	-61.48%	-66.01%
NET CHANGE
Cash From Operating Activities	-$624.1K	-754.8K	-$3.041M
Cash From Investing Activities
Cash From Financing Activities	$515.7K	474.2K	$1.368M
Net Change In Cash	-$110.3K	-280.6K	-$1.675M
YoY Change	-82.38%	-109.84%	-155.64%
FREE CASH FLOW
Cash From Operating Activities	-$624.1K	-$754.8K	-$3.041M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000315545
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	PVCT	Deposit For Purchase Of Preferred Stock DepositForPurchaseOfPreferredStock		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	PVCT	Adjustments To Additional Paid In Capital Conversion Of Series B Preferred Stock To Common Stock AdjustmentsToAdditionalPaidInCapitalConversionOfSeriesBPreferredStockToCommonStock		usd
CY2021	PVCT	Adjustments To Additional Paid In Capital Conversion Of Series D1 Preferred Stock To Common Stock AdjustmentsToAdditionalPaidInCapitalConversionOfSeriesD1PreferredStockToCommonStock		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	PVCT	Deposit Applied To Equity Issuances DepositAppliedToEquityIssuances		usd
CY2022	PVCT	Conversion Of Nonamended Notes To Preferred Stock ConversionOfNonamendedNotesToPreferredStock		usd
CY2022	PVCT	Conversion Of Amended Notes And Notes To Preferred Stock One ConversionOfAmendedNotesAndNotesToPreferredStockOne		usd
CY2022	PVCT	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2021	PVCT	Conversion Of Notes To Preferred Stock ConversionOfNotesToPreferredStock		usd
CY2021	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2021Q4	PVCT	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36457
CY2022	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0031917
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 S Gay St
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1610
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Knoxville
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37929
CY2022	dei	City Area Code CityAreaCode	866
CY2022	dei	Local Phone Number LocalPhoneNumber	594-5999
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	22587552	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	419497119	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, CA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21605	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	682984	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1410102	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2423958	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	394	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5107	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	467081	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	329908	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1899182	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3441957	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	102073	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	91178	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20941	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31836	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117123	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39563	usd
CY2022Q4	us-gaap	Assets Assets	2037246	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2094258	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1287459	usd
CY2021Q4	PVCT	Deposit For Purchase Of Preferred Stock DepositForPurchaseOfPreferredStock	150000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2021Q4	us-gaap	Assets Assets	3513356	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2500000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002486	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	30844	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10578	usd
CY2022Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	40992	usd
CY2021Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	6044	usd
CY2022Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	239394	usd
CY2021Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	238452	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	625000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1260000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1202500	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	200000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44422	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45617	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8192380	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7700636	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73376	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8265756	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7700636	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419497119	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419497119	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419447119	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419447119	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	419497	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	419447	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	242954193	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241440106	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35679	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34467	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-249588641	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246033958	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2037246	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3513356	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	989042	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2389360	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2608357	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2027628	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2063897	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4416988	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	4672254	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3427946	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4672254	usd
CY2022	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	36954	usd
CY2021	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	31315	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63094	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-163691	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-961698	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-126737	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-867289	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5539543	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419470338	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	408223004	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5539543	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1212	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-370	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3555895	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5539913	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-30206357	usd
CY2021	PVCT	Stock Issued During Period Value Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuedUponExerciseOfWarrants	962223	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23199	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	488	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3541222	usd
CY2021	PVCT	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	27031858	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5539543	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-370	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3025	usd
CY2022	PVCT	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	1361640	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1212	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5539543	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3025	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23688	usd
CY2022	PVCT	Noncash Lease Expense NoncashLeaseExpense	52883	usd
CY2021	PVCT	Noncash Lease Expense NoncashLeaseExpense	81258	usd
CY2022	us-gaap	Depreciation Depreciation	10895	usd
CY2021	us-gaap	Depreciation Depreciation	12865	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63094	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4481	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1449	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-122914	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-265957	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	807073	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	331148	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-989042	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2500000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	402390	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	502581	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58262	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-83549	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	156854	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	956834	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3041472	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1013304	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	625000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2960000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1002500	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	259659	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	248177	usd
CY2021	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	-150000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	962223	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1367841	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4024046	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1604	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1031	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1675235	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3009711	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97231	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21605	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	682984	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1410102	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	2423958	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2022	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-203175	usd
CY2021	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-273347	usd
CY2022	PVCT	Deposit Applied To Equity Issuances DepositAppliedToEquityIssuances	-150000	usd
CY2021	PVCT	Conversion Of Nonamended Notes To Preferred Stock ConversionOfNonamendedNotesToPreferredStock	3541222	usd
CY2021	PVCT	Conversion Of Amended Notes And Notes To Preferred Stock One ConversionOfAmendedNotesAndNotesToPreferredStockOne	27031858	usd
CY2021	PVCT	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	222	usd
CY2022	PVCT	Conversion Of Notes To Preferred Stock ConversionOfNotesToPreferredStock	1361640	usd
CY2022	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability	-130443	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zCkwBd5AS5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_826_zij65XuxYD85">Business Organization and Nature of Operations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-modulators called halogenated xanthenes (“HXs”). Our lead molecule is named rose bengal sodium (“RBS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair depending on the disease being treated and the concentration of the RBS utilized in the treatment. Secondly, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry ClinicalTrials.gov.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first and only entity to date to successfully, reproducibly, and consistently make pharmaceutical-grade RBS at a purity of nearly 100%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s small molecule HX medical science platform comprises a number of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept <i>in vivo</i> drug discovery programs in oncology, hematology, wound healing, and animal health; and preclinical <i>in vitro</i> drug discovery programs in infectious diseases and tissue regeneration and repair.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Risks and Uncertainties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Severe acute respiratory syndrome (“SARS”) coronavirus (“CoV”) 2 (“SARS-CoV-2”) was first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1410102	usd
CY2022Q4	PVCT	Working Capital Deficiency WorkingCapitalDeficiency	6293198	usd
CY2021Q4	PVCT	Working Capital Deficiency WorkingCapitalDeficiency	4258679	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zcZMgtQCZ0Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z9KkV6QswZCg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	42594	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2021Q4	PVCT	Payment To Vendors For Expense And Deposits PaymentToVendorsForExpenseAndDeposits	1089898	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zTpVmcFIYLV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z5dTaNXbBhr9">Cash Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zVMmt7w12uc1" title="Insured limits">250,000</span>, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of December 31, 2022 and 2021, the Company had cash, cash equivalent, and restricted cash balances in excess of FDIC insurance limits of $<span id="xdx_902_eus-gaap--FDICIndemnificationAsset_iI_c20221231_zlDvtGuNtHB5" title="Cash in excess FDIC insured amount">1,181,707</span> and $<span id="xdx_901_eus-gaap--FDICIndemnificationAsset_iI_c20211231_zbZds4GlVld9" title="Cash in excess FDIC insured amount">2,856,942</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1181707	usd
CY2021Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	2856942	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	25000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	120375901	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	108695237	shares
CY2022Q4	PVCT	Foreign Currency Translation Adjustments Of Assets ForeignCurrencyTranslationAdjustmentsOfAssets	17373	usd
CY2021Q4	PVCT	Foreign Currency Translation Adjustments Of Assets ForeignCurrencyTranslationAdjustmentsOfAssets	383447	usd
CY2022Q4	PVCT	Foreign Currency Translation Adjustments Of Liabilities ForeignCurrencyTranslationAdjustmentsOfLiabilities	22053	usd
CY2021Q4	PVCT	Foreign Currency Translation Adjustments Of Liabilities ForeignCurrencyTranslationAdjustmentsOfLiabilities	407851	usd
CY2022	PVCT	Foreign Currency Translation Adjustment Of Expense And Other Income ForeignCurrencyTranslationAdjustmentOfExpenseAndOtherIncome	4503	usd
CY2021	PVCT	Foreign Currency Translation Adjustment Of Expense And Other Income ForeignCurrencyTranslationAdjustmentOfExpenseAndOtherIncome	85052	usd
CY2021	PVCT	Weighted Average Exercise Price Granted WeightedAverageExercisePriceGranted	0.29
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	18052966	shares
CY2021	PVCT	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0.05
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	314160	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	174533	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	69077	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	42871	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945589	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1560589	usd
CY2022Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	75186	usd
CY2021Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	224493	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002486	usd
CY2020Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	23392000	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3160000	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	25092000	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1460000	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1627500	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1260000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1827500	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	25092000	usd
CY2021	PVCT	Accrued Interest Converted AccruedInterestConverted	5481080	usd
CY2021	PVCT	Debt Conversion Converted Instrument Net DebtConversionConvertedInstrumentNet	30573080	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	21813841	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	68723698	shares
CY2021	PVCT	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0.05
CY2022Q4	us-gaap	Notes Payable NotesPayable	239394	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	238452	usd
CY2022	us-gaap	Officers Compensation OfficersCompensation	385000	usd
CY2021	us-gaap	Officers Compensation OfficersCompensation	385000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1945589	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1560589	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	PVCT	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	1385000	shares
CY2021Q4	PVCT	Stated Value StatedValue	2500	usd
CY2021Q4	us-gaap	Cumulative Dividends CumulativeDividends	1000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4800000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1175000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.89
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3625000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.32
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.86
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3425000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3425000	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y9M
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3425000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	68723698	shares
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	87264164	shares
CY2020Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.02
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	512500	shares
CY2021Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.92
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	37500	shares
CY2022	PVCT	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0.29
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	475000	shares
CY2022Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.97
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	475000	shares
CY2022	PVCT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2	P1Y3M14D
CY2022Q4	PVCT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	475000	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3550182	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5454489	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4501	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-85053	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3554683	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5539542	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	538915	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	295524	usd
CY2022	PVCT	Effective Income Tax Rate Reconciliation State And Local Deferred Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalDeferredIncomeTaxes	0.0514	pure
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	131778	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	72262	usd
CY2022	PVCT	Effective Income Tax Rate Reconciliation Federal State And Local Income Taxes EffectiveIncomeTaxRateReconciliationFederalStateAndLocalIncomeTaxes	0.2614	pure
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	670693	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	367786	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	670693	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	367786	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.051	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.051	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.037	pure
CY2021	PVCT	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.009	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.186	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.072	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Prior Year Trueup EffectiveIncomeTaxRateReconciliationPriorYearTrueup	0.023	pure
CY2021	PVCT	Effective Income Tax Rate Reconciliation Prior Year Trueup EffectiveIncomeTaxRateReconciliationPriorYearTrueup	0.024	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss Carry Forwards Percentage EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLossCarryForwardsPercentage	0.491	pure
CY2021	PVCT	Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss Carry Forwards Percentage EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLossCarryForwardsPercentage	0.068	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Expiration Of Warrants And Options EffectiveIncomeTaxRateReconciliationExpirationOfWarrantsAndOptions	0.010	pure
CY2021	PVCT	Effective Income Tax Rate Reconciliation Expiration Of Warrants And Options EffectiveIncomeTaxRateReconciliationExpirationOfWarrantsAndOptions	0.036	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Conversion Of Accrued Interest To Preferred Stock EffectiveIncomeTaxRateReconciliationConversionOfAccruedInterestToPreferredStock	0.0000	pure
CY2021	PVCT	Effective Income Tax Rate Reconciliation Conversion Of Accrued Interest To Preferred Stock EffectiveIncomeTaxRateReconciliationConversionOfAccruedInterestToPreferredStock	0.214	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Miscellaneous EffectiveIncomeTaxRateReconciliationMiscellaneous	-0.007	pure
CY2021	PVCT	Effective Income Tax Rate Reconciliation Miscellaneous EffectiveIncomeTaxRateReconciliationMiscellaneous	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42012057	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43453746	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3229869	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3049608	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	152813	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	186772	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	337558	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	227397	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	358897	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	10062	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	10062	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	628265	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	505038	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46729521	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47432623	usd
CY2022Q4	PVCT	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	3915	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	86459	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	82179	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	40604	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	90374	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	122783	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46639147	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47309840	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	670693	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	367786	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	19900000	usd
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	the U.S. federal and Tennessee tax years open to examination are 2019 through 2022. The Australia income tax return remains open to examination for 2020 through 2022.
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	62944	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	82678	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	130422	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	49311	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50663	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	25669	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	125643	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7845	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	117798	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	989042	usd
CY2022	PVCT	License Transaction Description LicenseTransactionDescription	the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis.

Files In Submission

Name	View Source	Status
pvct-20221231_cal.xml	Edgar Link	unprocessable
0001493152-23-009563-index-headers.html	Edgar Link	pending
0001493152-23-009563-index.html	Edgar Link	pending
0001493152-23-009563.txt	Edgar Link	pending
0001493152-23-009563-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
pvct-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
pvct-20221231_def.xml	Edgar Link	unprocessable
pvct-20221231_lab.xml	Edgar Link	unprocessable
pvct-20221231_pre.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2023 Q1 Form 10-K Financial Statement

#000149315223009563 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2023 Q1 Form 10-K Financial Statement

#000149315223009563 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct